Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 27, 2025

Muscle-invasive bladder cancer (MIBC) is an aggressive characterized by invasion of the muscular wall, often necessitating a multimodal treatment approach for optimal outcomes. This study aimed to compare real-world efficacy and safety disitamab vedotin (RC48), antibody-drug conjugate (ADC), combined immunotherapy targeting programmed cell death protein-1 (PD-1), against gemcitabine cisplatin (GC) regimen with PD-1 in MIBC. single-center, retrospective was conducted at First Affiliated Hospital Soochow University included 38 patients MIBC treated either RC48 plus or GC immunotherapy, between January 2022 December 2023. Patients were divided into two groups: (ADC + PD-1) group (GC group. Efficacy evaluated based on their pathological complete response rates (PCRR) downstaging (PDR). Adverse events (AEs) assessed profiles. Of patients, 17 ADC 21 The PCRR significantly higher (82.35%, 14/17) compared (47.62%, 10/21; P = 0.043). PDR also (94.12%, 16/17) than (80.95%, 17/21), although difference not statistically significant (P 0.355). No serious allergic reactions fatal AEs reported Grade 4 reported, while 3 occurred rate 5.71% 12.20% 0.260). demonstrated maintaining comparable profile. These findings highlight potential as effective option clinical practice.

Language: Английский

Development and validation of a predictive model for postoperative metastasis of upper tract urothelial carcinoma after radical nephroureterectomy and analysis of risk factors for different metastatic sites: a multicenter study

International Urology and Nephrology, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Language: Английский

Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Sept. 13, 2024

For patients with metastatic upper tract urothelial carcinoma (UTUC), the preferred first-line treatment is platinum-based chemotherapy. Immunotherapy can be considered a subsequent if chemotherapy ineffective or disease progresses. However, how should administered immunotherapy useless and patient cannot take chemotherapy? Especially in who have metastasized after radical nephroureterectomy (RNU).

Language: Английский